Tivic Health Systems Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名157/206位。机构持股占比非常高,中期看,股价处于下降通道。近一个月,市场表现较强,基本面评分较高,但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Tivic Health Systems Inc评分
相关信息
行业排名
157 / 206
全市场排名
500 / 4562
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Tivic Health Systems Inc亮点
亮点风险
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
公司代码TIVC
公司Tivic Health Systems Inc
CEOErnst (Jennifer)
网址https://tivichealth.com/
常见问题
Tivic Health Systems Inc(TIVC)的当前股价是多少?
Tivic Health Systems Inc(TIVC)的当前股价是 1.890。
Tivic Health Systems Inc的股票代码是什么?
Tivic Health Systems Inc的股票代码是TIVC。
Tivic Health Systems Inc股票的52周最高点是多少?
Tivic Health Systems Inc股票的52周最高点是15.640。
Tivic Health Systems Inc股票的52周最低点是多少?
Tivic Health Systems Inc股票的52周最低点是1.470。
Tivic Health Systems Inc的市值是多少?
Tivic Health Systems Inc的市值是3.14M。
Tivic Health Systems Inc的净利润是多少?
Tivic Health Systems Inc的净利润为-5.66M。
现在Tivic Health Systems Inc(TIVC)的股票是买入、持有还是卖出?
根据分析师评级,Tivic Health Systems Inc(TIVC)的总体评级为--,目标价格为--。
Tivic Health Systems Inc(TIVC)股票的每股收益(EPS TTM)是多少
Tivic Health Systems Inc(TIVC)股票的每股收益(EPS TTM)是-322.802。